Novartis Investigative Site

Kecskemét 6001

0 studies enrolling now · 10 studies all time

What they study most

Adrenocortical Adenoma, Atherosclerotic Cardiovascular Disease, Breast Neoplasms, Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Early Breast Cancer, Endometrial Stromal Sarcomas, Hidradenitis Suppurativa, Leukaemia, Lymphocytic, Chronic, Neoplasms, Gastrointestinal Tract, Partial Onset Seizures

Studies at this site

• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• Phase II BGG492 Capsule Extension for Partial Epilepsy — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures — Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 — Completed